Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $115.00

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given a consensus rating of “Hold” by the twenty-one analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $117.1875.

A number of equities analysts recently commented on the stock. Cowen reiterated a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Canaccord Genuity Group lifted their price target on Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. UBS Group increased their price objective on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Barclays raised their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, November 8th.

Illumina Price Performance

Shares of Illumina stock opened at $129.56 on Thursday. The business’s 50-day moving average price is $116.72 and its 200-day moving average price is $103.77. The firm has a market capitalization of $19.80 billion, a PE ratio of 29.05, a price-to-earnings-growth ratio of 2.35 and a beta of 1.44. Illumina has a 12 month low of $68.70 and a 12 month high of $153.06. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period last year, the business earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Sell-side analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Illumina

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. increased its holdings in Illumina by 10.2% in the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after buying an additional 99 shares during the period. Versant Capital Management Inc grew its stake in shares of Illumina by 8.9% in the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the period. Finally, Archer Investment Corp lifted its position in Illumina by 12.9% during the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.